Search

Your search keyword '"Merino, L."' showing total 62 results

Search Constraints

Start Over You searched for: Author "Merino, L." Remove constraint Author: "Merino, L." Publisher elsevier b.v. Remove constraint Publisher: elsevier b.v.
62 results on '"Merino, L."'

Search Results

Catalog

Books, media, physical & digital resources

9. Traditional organic additives improve lime mortars: new old materials for restoration and building natural stone fabrics

10. Desarrollo de un protocolo de monitorización de fuga en perfusión de miembro aislado con gammacámara portátil.

11. Periodic urban models for optimization of passive solar irradiation.

12. Oxidative stability of iron fortified goat and cow milk and their peptide isolates.

13. Assessing the iron chelation capacity of goat casein digest isolates.

16. Steady shear flow behavior of gum extracted from Ocimum basilicum L. seed: Effect of concentration and temperature

17. 2000 years of pastoralism and fire shaping high-altitude vegetation of Sierra de Gredos in central Spain

18. Starch–fenugreek (Trigonella foenum-graecum L.) polysaccharide interactions in pure and soup systems

19. (As,Sb)In/GaInSb quantum well for infrared detection enhancement

21. Survival and germination of Mediterranean grassland species after simulated sheep ingestion: ecological correlates with seed traits

24. Multimodal prehabilitation: a promising strategy in patients listed for heart transplantation.

25. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.

28. 1078MO Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716.

29. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2–advanced breast cancer: GEICAM/2014–12 (FLIPPER).

30. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.

31. LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004.

32. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

33. 813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study.

34. 42TiP A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors.

35. The effect of lactoferrin on physical changes in phospholipid stabilised emulsions during neonatal in vitro gastric digestion: Does synergism of pepsin and lipase promote lipolysis in protein-stabilised emulsions?

36. 823P A propensity score weighted comparison of tebentafusp or pembrolizumab versus combination ipilimumab and nivolumab in untreated metastatic uveal melanoma.

37. Factors influencing the dynamics of emulsion structure during neonatal gastric digestion in an in vitro model.

39. 1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238.

41. Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024]

42. 94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study.

43. LBA19 GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs) F/placebo (PL) as first-line therapy in postmenopausal women with HR (hormone receptor)+/HER2– endocrine sensitive advanced breast cancer (ABC)

46. PMU23 COST OF ILLNESS IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS DISEASE. COEPSO STUDY.

48. 88PRun-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast.